Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both
about
Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. cariniiRandomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerHIV: primary and secondary prophylaxis for opportunistic infections.Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii.Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing?Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.Antiparasitic agent atovaquoneGuidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theChemotherapy for patients with multiple parasitic infections.Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management.Projected survival gains from revising state laws requiring written opt-in consent for HIV testing.Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions.2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapyCost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.Management of Pneumocystis pneumonia in patients with inflammatory disorders.An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Improving outcomes in state AIDS drug assistance programs.Pneumocystis infection in humans: diagnosis and treatment.Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients.Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.How well is the clinical importance of study results reported? An assessment of randomized controlled trials.The management of Pneumocystis carinii pneumonia.Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.Cardiac toxoplasmosis after heart transplantation diagnosed by endomyocardial biopsy.Pneumocystis pneumonia in solid organ transplantation.Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Rec2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae.Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin.Pneumocystis Pneumonia in Solid-Organ Transplant Recipients.Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.
P2860
Q28343926-7C63AAB1-8625-4F15-BACA-FDCB008E3358Q30847884-9BE2ABF6-A44E-42F7-AE92-78D65AA85945Q33228693-8944FF48-2699-4DF3-9CA2-4E06D05E5345Q33650105-F8754576-15ED-4B24-A6BF-8234D17D4051Q33850498-DA7A88F4-EBC4-49A1-9D44-A4EE238850DBQ33982091-392A1913-F6BF-4416-AE7F-473C2D5CE62CQ34004404-F8644449-A307-42AD-8582-2B3ADB38D381Q34004622-E8E846C4-9AA0-4391-9883-877320D28720Q34107885-D26D0DC0-4351-4615-8AF5-6C3A518C94CEQ34212799-7DD80FE3-371F-4FAB-BE3F-ECD8BE9FA88BQ34301460-565F9BD9-AB52-47DA-8553-90D19F03C837Q34393599-3FAB2EA3-0FE6-423C-9B61-7DC5D8FD8510Q34459389-E6060DD2-C313-47F5-9D35-B559C923A1A5Q35007043-EB308B92-28B3-4F7B-B6AA-F2F032D8762BQ35557252-5432AF0F-47E2-40B5-BDBA-8ACAE0D61BC0Q35614631-5ADF0D51-6D3E-49A2-8039-247F7F048726Q35657599-8E9E2623-86DF-477F-9841-B5CFA8324D6FQ35689246-3C970A28-4BE6-4B8B-8F0B-A7CDF030350AQ35692811-EF581281-B1DA-4F97-92F6-8DD70E351BC9Q35920640-40A6E23A-D59A-45B7-9956-FAA84389BAC9Q36162376-71D266AD-9D9E-4661-B194-F72C95DBC493Q36616349-E791BC6C-1B68-4088-BBDD-86DE3691E849Q37150434-9A7ACC3A-3EBA-49DE-A3CD-A688902AF2EFQ37180338-90BAC27A-B5EB-4BCF-A1E6-27FD7B20CBBAQ37415433-466B3125-83BF-4A13-950A-7AAC2C279016Q37762544-4D74B817-D8A0-49ED-96C2-5EE9E2104605Q38364906-125FE870-B5B1-4A82-9469-DD6472650361Q38647546-8A6DBE41-EE5F-4CF9-86A4-B98502834353Q38934525-62B9F610-881B-4E2C-BEF2-DA1EF00AF88EQ39434130-33CEBEEE-FFBE-4023-818C-C909EF8B228EQ39560836-50AB7B36-95A1-4426-9B28-4E39BF09FDBBQ40092648-356FB648-9F1E-456C-BFF9-CFE7C70F6C87Q40816149-DD50509F-AE4D-442F-84E9-726BC27859F3Q42272280-1903256E-31F9-4464-B98C-9C88479EB5DDQ43952836-C6223D87-71FA-4F5A-B189-D2676E4E63EDQ44616568-6B3F05CC-2BD5-4C9A-A654-090F3A6F4FD7Q44630376-7C4AC785-7250-48A4-A76B-82488E2E6FE6Q46601999-368B30E2-F189-4791-A612-D49F56544973Q48149271-593B8C1E-61ED-4FF7-B523-1F39908B95B7Q51559180-50C1D7F0-891F-4A49-8D64-EB102D9EE7BB
P2860
Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both
description
article
@en
im Dezember 1998 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1998
@uk
name
Atovaquone Compared with Dapso ...... thoprim, Sulfonamides, or Both
@en
Atovaquone Compared with Dapso ...... thoprim, Sulfonamides, or Both
@nl
type
label
Atovaquone Compared with Dapso ...... thoprim, Sulfonamides, or Both
@en
Atovaquone Compared with Dapso ...... thoprim, Sulfonamides, or Both
@nl
prefLabel
Atovaquone Compared with Dapso ...... thoprim, Sulfonamides, or Both
@en
Atovaquone Compared with Dapso ...... thoprim, Sulfonamides, or Both
@nl
P2093
P50
P1476
Atovaquone Compared with Dapso ...... thoprim, Sulfonamides, or Both
@en
P2093
Henry H. Balfour
Malte Schutz
Richard Hafner
Robert Eng
Roberta Luskin-Hawk
Teresa McCabe Yurik
Thomas M. Hooton
Thomas M. Kerkering
Tony W. Cheung
P304
P356
10.1056/NEJM199812243392604
P407
P577
1998-12-24T00:00:00Z